Net Cash Provided by (Used in) Financing Activities in USD of Marker Therapeutics, Inc. from 2010 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Marker Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and change rate from 2010 to Q1 2025.
  • Marker Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $505.000.
  • Marker Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $15M, a 1257% increase from 2023.
  • Marker Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $1.11M, a 447% increase from 2022.
  • Marker Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $202K, a 99.6% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

Marker Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $505* -$48.6K 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025
Q1 2024 $49.1K -$571K -92.1% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025
Q1 2023 $620K +$620K 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024
Q1 2022 $0 -$52.7M -100% 01 Jan 2022 31 Mar 2022 10-Q 13 May 2022
Q1 2021 $52.7M +$52.1M +9474% 01 Jan 2021 31 Mar 2021 10-Q 13 May 2022
Q1 2020 $550K +$487K +771% 01 Jan 2020 31 Mar 2020 10-Q 12 May 2021
Q1 2019 $63.1K +$45K +248% 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020
Q1 2018 $18.1K +$18.1K 01 Jan 2018 31 Mar 2018 10-Q 10 May 2019
Q1 2017 $0 +$25K 01 Jan 2017 31 Mar 2017 10-Q 15 May 2018
Q1 2016 -$25K -$2.35M -101% 01 Jan 2016 31 Mar 2016 10-Q 16 May 2016
Q1 2015 $2.33M +$1.91M +456% 01 Jan 2015 31 Mar 2015 10-Q 16 May 2016
Q1 2014 $418K -$7.05K -1.66% 01 Jan 2014 31 Mar 2014 10-Q/A 14 Apr 2016
Q1 2013 $425K +$319K +301% 01 Jan 2013 31 Mar 2013 10-Q/A 21 May 2014
Q1 2012 $106K -$313K -74.7% 01 Jan 2012 31 Mar 2012 10-Q/A 19 Aug 2013
Q1 2011 $418K 01 Jan 2011 31 Mar 2011 10-Q 21 May 2012

Marker Therapeutics, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $15M +$13.9M +1257% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025
2023 $1.11M +$903K +447% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025
2022 $202K -$52.4M -99.6% 01 Jan 2022 31 Dec 2022 10-K 26 Mar 2024
2021 $52.6M +$45.8M +680% 01 Jan 2021 31 Dec 2021 10-K 22 Mar 2023
2020 $6.74M +$5.92M +725% 01 Jan 2020 31 Dec 2020 10-K 17 Mar 2022
2019 $816K -$70.4M -98.9% 01 Jan 2019 31 Dec 2019 10-K 09 Mar 2021
2018 $71.2M +$65.5M +1146% 01 Jan 2018 31 Dec 2018 10-K 12 Mar 2020
2017 $5.72M -$2.07M -26.6% 01 Jan 2017 31 Dec 2017 10-K 15 Mar 2019
2016 $7.78M -$2.99M -27.8% 01 Jan 2016 31 Dec 2016 10-K 23 Mar 2018
2015 $10.8M +$8.5M +373% 01 Jan 2015 31 Dec 2015 10-K 14 Apr 2016
2014 $2.28M +$1.57M +221% 01 Jan 2014 31 Dec 2014 10-K 14 Apr 2016
2013 $709K -$656K -48.1% 01 Jan 2013 31 Dec 2013 10-K 15 Apr 2015
2012 $1.37M -$171K -11.1% 01 Jan 2012 31 Dec 2012 10-K 15 May 2013
2011 $1.54M +$729K +90.4% 01 Jan 2011 31 Dec 2011 10-K 15 May 2013
2010 $807K 01 Jan 2010 31 Dec 2010 10-K 16 Apr 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.